Journal profile · PHARMACOLOGY & PHARMACY
Clinical Pharmacology-Advances and Applications
ISSN 1179-1438 · Dove Medical Press · United Kingdom
Clinical Pharmacology-Advances and Applications: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.2 (journal website); fully open access; APC about USD 3,565; median 95 days to acceptance (40 articles, last 24 months); acceptance rate 26% (journal website); 23 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Clinical Pharmacology-Advances and Applications is published by Dove Medical Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Atrial Fibrillation Management and Outcomes and Antibiotics Pharmacokinetics and Efficacy, together about 21.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Professor Arthur E Frankel Clinical Pharmacology: Advances and Applications is an international, peer-reviewed, open access, online journal, that focuses on the publication of clinical trials and study protocols with a special interest in pharmacologic behavior of drugs and agents. Clinical Pharmacology: Advances and Applications will no longer consider meta-analyses for publication. The journal aims to serve both the academic and industrial communities and it is dedicated to publishing rapidly all scientifically sound clinical trials and study protocols. Clinical trials submitted to the journal should report detailed pharmacologic information/data. The journal aims at publishing articles that will allow predictions to be made from drug chemistry and pharmacology for eventual benefits and side effects. Clinical Pharmacology: Advances and Applications provides the best available evidence to support decisions related to the safety and efficacy of vaccines, drugs and medical devices for use by patients. The journal considers original research, study protocols, methodology papers, short reports, reviews and commentaries in all areas of drug experience in humans. Updated 8 September 2025
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Editor-in-chief Frankel ChiefPublisher website
Editorial board by country: 7 in mainland China (about 14%); most named United States 34, Mainland China 7, Canada 4, Germany 2, Israel 2 (50 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Treatment and ManagementMedicine8.3%
- Atrial Fibrillation Management and OutcomesMedicine7.5%
- Antibiotics Pharmacokinetics and EfficacyMedicine6.1%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics5.7%
- Antiplatelet Therapy and Cardiovascular DiseasesMedicine5.3%
- Anesthesia and Sedative AgentsMedicine4%
- Metabolism, Diabetes, and CancerBiochemistry, Genetics and Molecular Biology4%
- Cancer Treatment and PharmacologyMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
SJR, CiteScore, Impact FactorPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.2Publisher website ·
- 5-year impact factor (publisher)
- 4Publisher website ·
- CiteScore 2026-06
- 4LetPub ·
- CiteScore (publisher) 2025
- 0.64Publisher website ·
- SJR 2026-06
- 0.41LetPub ·
- SNIP 2026-06
- 0.64LetPub ·
- h-index
- 42OpenAlex ·
- i10-index
- 149OpenAlex ·
- 2-year mean citedness
- 2.67OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 23LetPub ·
- Downloads per year (publisher)
- 48,868Publisher website ·
Articles by year OpenAlex count · 310 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 16 | 16 | 2 |
| 2025 | 23 | 23 | 77 |
| 2024 | 3 | 3 | 33 |
| 2023 | 12 | 12 | 61 |
| 2022 | 12 | 12 | 118 |
| 2021 | 27 | 27 | 375 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
95 daysMedian, submission to acceptance · P25–P75 75 days – 111 days
- Acceptance to online
- median 11 days (40 articles)
- Submission to online
- median 108 days
- Sample
- 40 articles with submission and acceptance dates (40 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 26%Publisher website ·
- Desk decision
- 45 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,565 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics
- Publication ethics
Member of and subscribes to the principles of the Committee on Publication Ethics (COPE) Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1179-1438
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Clinical Pharmacology-Advances and Applications
What CAS zone is Clinical Pharmacology-Advances and Applications in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Pharmacology-Advances and Applications is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Pharmacology-Advances and Applications?
The journal's website gives an impact factor of 2.2 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4, h-index 42.
How long does peer review take at Clinical Pharmacology-Advances and Applications?
Based on the dates recorded on 40 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 95 days (interquartile range 75–111 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 26%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Clinical Pharmacology-Advances and Applications based?
Of the 50 board members whose country the journal's board page names, 7 (about 14%) are in mainland China; the countries named most often are United States (34), Mainland China (7) and Canada (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Pharmacology-Advances and Applications?
According to LetPub and DOAJ records, Clinical Pharmacology-Advances and Applications is indexed in ESCI, Scopus and DOAJ.
Is Clinical Pharmacology-Advances and Applications open access, and what is the APC?
Clinical Pharmacology-Advances and Applications is a fully open-access journal. APC about USD 3,565.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .